Icon Cancer Foundation announces new Deputy Director of Cellular Therapy

“I am thrilled to take on this new role and look forward to contributing to the advancement of cellular therapy in Australia,” Dr Nath said.

“I am particularly interested in improving access to CAR T-cell therapy for our patients in Australia.”

CAR T-cell therapy is a type of immunotherapy where a patient’s own immune system is re-engineered to destroy cancerous cells.
A patient’s cells are removed , modified with new proteins to recognise the cancer, and then returned to the patient’s body in large numbers to combat the cancer.
This innovative therapy is proven to be highly effective for patients with blood cancers such as lymphoma, myeloma and acute lymphoblastic leukemia (ALL) and are also being explored as a treatment for other cancers including breast, gastric and kidney cancers.

“In my new role, I am dedicated to improving the availability of this treatment option, and ultimately providing the best possible care for our patients,” Dr Nath said

“My research interest includes exploring ways to make CAR T-cell therapy safer, with fewer side effects.”

This appointment, made possible by the generous contribution of an anonymous benefactor, is set to significantly enhance research in cellular therapy in Australia. Stay tuned for more updates on this exciting development.